CA2391226A1 - Reduced side-effect hemoglobin compositions - Google Patents

Info

Publication number

CA2391226A1

CA2391226A1 CA002391226A CA2391226A CA2391226A1 CA 2391226 A1 CA2391226 A1 CA 2391226A1 CA 002391226 A CA002391226 A CA 002391226A CA 2391226 A CA2391226 A CA 2391226A CA 2391226 A1 CA2391226 A1 CA 2391226A1

Authority

CA

Canada

Prior art keywords

fwdarw

leu

trp

hemoglobin

val

Prior art date

1999-11-12

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 108010054147 Hemoglobins Proteins 0.000 title claims abstract description 992
• 102000001554 Hemoglobins Human genes 0.000 title claims abstract description 988
• 239000000203 mixture Substances 0.000 title claims abstract description 100
• 230000002829 reductive effect Effects 0.000 title claims description 188
• 230000003902 lesion Effects 0.000 claims abstract description 115
• 239000002158 endotoxin Substances 0.000 claims abstract description 38
• 230000002315 pressor effect Effects 0.000 claims abstract description 35
• 206010021137 Hypovolaemia Diseases 0.000 claims abstract description 26
• 206010019196 Head injury Diseases 0.000 claims abstract description 19
• 230000011132 hemopoiesis Effects 0.000 claims abstract description 19
• 230000035939 shock Effects 0.000 claims abstract description 17
• 208000032843 Hemorrhage Diseases 0.000 claims abstract description 16
• 208000007502 anemia Diseases 0.000 claims abstract description 15
• 206010007625 cardiogenic shock Diseases 0.000 claims abstract description 13
• 230000002708 enhancing effect Effects 0.000 claims abstract description 11
• 206010006895 Cachexia Diseases 0.000 claims abstract description 8
• 230000004936 stimulating effect Effects 0.000 claims abstract description 7
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 247
• 230000035772 mutation Effects 0.000 claims description 211
• INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 claims description 201
• 230000000694 effects Effects 0.000 claims description 162
• 239000000243 solution Substances 0.000 claims description 149
• 238000000034 method Methods 0.000 claims description 133
• 239000008194 pharmaceutical composition Substances 0.000 claims description 120
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 102
• 239000001301 oxygen Substances 0.000 claims description 102
• 229910052760 oxygen Inorganic materials 0.000 claims description 102
• 241000124008 Mammalia Species 0.000 claims description 65
• 210000004027 cell Anatomy 0.000 claims description 57
• 210000004369 blood Anatomy 0.000 claims description 54
• 239000008280 blood Substances 0.000 claims description 54
• 230000037396 body weight Effects 0.000 claims description 45
• 150000003278 haem Chemical class 0.000 claims description 45
• 230000002496 gastric effect Effects 0.000 claims description 39
• 230000015572 biosynthetic process Effects 0.000 claims description 36
• 108091005904 Hemoglobin subunit beta Proteins 0.000 claims description 35
• 108091005902 Hemoglobin subunit alpha Proteins 0.000 claims description 32
• 102100027685 Hemoglobin subunit alpha Human genes 0.000 claims description 32
• 102100021519 Hemoglobin subunit beta Human genes 0.000 claims description 32
• 238000009826 distribution Methods 0.000 claims description 32
• 238000001802 infusion Methods 0.000 claims description 30
• 230000010412 perfusion Effects 0.000 claims description 28
• 101710187052 Flavohemoprotein Proteins 0.000 claims description 26
• 230000001965 increasing effect Effects 0.000 claims description 24
• 238000012384 transportation and delivery Methods 0.000 claims description 24
• 230000003247 decreasing effect Effects 0.000 claims description 21
• 210000003743 erythrocyte Anatomy 0.000 claims description 21
• 238000002560 therapeutic procedure Methods 0.000 claims description 20
• 150000001413 amino acids Chemical class 0.000 claims description 19
• 206010033661 Pancytopenia Diseases 0.000 claims description 16
• 208000024389 cytopenia Diseases 0.000 claims description 16
• 102100039894 Hemoglobin subunit delta Human genes 0.000 claims description 15
• 108091005903 Hemoglobin subunit delta Proteins 0.000 claims description 15
• 239000012530 fluid Substances 0.000 claims description 15
• 102220278455 rs1554378291 Human genes 0.000 claims description 15
• 206010059484 Haemodilution Diseases 0.000 claims description 14
• 108010061951 Methemoglobin Proteins 0.000 claims description 14
• 239000003937 drug carrier Substances 0.000 claims description 14
• 230000006378 damage Effects 0.000 claims description 12
• 230000002000 scavenging effect Effects 0.000 claims description 12
• 230000003394 haemopoietic effect Effects 0.000 claims description 11
• 208000027418 Wounds and injury Diseases 0.000 claims description 10
• 238000011275 oncology therapy Methods 0.000 claims description 10
• 206010021138 Hypovolaemic shock Diseases 0.000 claims description 9
• 206010040560 shock Diseases 0.000 claims description 9
• 238000007917 intracranial administration Methods 0.000 claims description 8
• 102200048328 rs1801270 Human genes 0.000 claims description 7
• 238000001990 intravenous administration Methods 0.000 claims description 6
• 230000000302 ischemic effect Effects 0.000 claims description 6
• YSGSDAIMSCVPHG-UHFFFAOYSA-N valyl-methionine Chemical compound CSCCC(C(O)=O)NC(=O)C(N)C(C)C YSGSDAIMSCVPHG-UHFFFAOYSA-N 0.000 claims description 6
• 208000032456 Hemorrhagic Shock Diseases 0.000 claims description 5
• 102220619487 Protein mago nashi homolog_D73K_mutation Human genes 0.000 claims description 5
• 206010049771 Shock haemorrhagic Diseases 0.000 claims description 5
• 206010052428 Wound Diseases 0.000 claims description 5
• 238000011260 co-administration Methods 0.000 claims description 5
• 239000011800 void material Substances 0.000 claims description 5
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 4
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 4
• 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 4
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 4
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
• 238000002399 angioplasty Methods 0.000 claims description 4
• 208000030507 AIDS Diseases 0.000 claims description 3
• 108010085682 Hemoglobin A Proteins 0.000 claims description 3
• 102000007513 Hemoglobin A Human genes 0.000 claims description 3
• 102000003816 Interleukin-13 Human genes 0.000 claims description 3
• 108090000176 Interleukin-13 Proteins 0.000 claims description 3
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
• 239000004473 Threonine Substances 0.000 claims description 3
• 238000011049 filling Methods 0.000 claims description 3
• 238000010253 intravenous injection Methods 0.000 claims description 3
• 230000037452 priming Effects 0.000 claims description 3
• 239000002510 pyrogen Substances 0.000 claims description 3
• NTISAKGPIGTIJJ-IUCAKERBSA-N Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(C)C NTISAKGPIGTIJJ-IUCAKERBSA-N 0.000 claims description 2
• 108010091871 leucylmethionine Proteins 0.000 claims description 2
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
• 101100274557 Heterodera glycines CLE1 gene Proteins 0.000 claims 16
• 239000000725 suspension Substances 0.000 claims 10
• 108010092408 Eosinophil Peroxidase Proteins 0.000 claims 2
• 102100028471 Eosinophil peroxidase Human genes 0.000 claims 2
• 102100020880 Kit ligand Human genes 0.000 claims 2
• 101710177504 Kit ligand Proteins 0.000 claims 2
• 210000002216 heart Anatomy 0.000 abstract description 58
• 238000011282 treatment Methods 0.000 abstract description 28
• 230000001225 therapeutic effect Effects 0.000 abstract description 26
• 206010040642 Sickle cell anaemia with crisis Diseases 0.000 abstract description 15
• 206010028980 Neoplasm Diseases 0.000 abstract description 13
• 208000006011 Stroke Diseases 0.000 abstract description 12
• 208000028867 ischemia Diseases 0.000 abstract description 10
• 206010020751 Hypersensitivity Diseases 0.000 abstract description 8
• 208000026935 allergic disease Diseases 0.000 abstract description 7
• 230000009610 hypersensitivity Effects 0.000 abstract description 7
• 206010000059 abdominal discomfort Diseases 0.000 abstract description 6
• 201000011510 cancer Diseases 0.000 abstract description 4
• 230000008439 repair process Effects 0.000 abstract description 3
• 238000006243 chemical reaction Methods 0.000 description 78
• 241001465754 Metazoa Species 0.000 description 70
• 229920001223 polyethylene glycol Polymers 0.000 description 55
• 108090000623 proteins and genes Proteins 0.000 description 49
• 210000001519 tissue Anatomy 0.000 description 48
• 108091006905 Human Serum Albumin Proteins 0.000 description 46
• 102000008100 Human Serum Albumin Human genes 0.000 description 46
• 239000012634 fragment Substances 0.000 description 44
• 235000018102 proteins Nutrition 0.000 description 38
• 102000004169 proteins and genes Human genes 0.000 description 38
• 241000700159 Rattus Species 0.000 description 34
• 238000012360 testing method Methods 0.000 description 34
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 33
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 31
• 108060003196 globin Proteins 0.000 description 31
• 239000013612 plasmid Substances 0.000 description 29
• 239000000047 product Substances 0.000 description 29
• 230000009257 reactivity Effects 0.000 description 29
• 238000007792 addition Methods 0.000 description 28
• 230000004044 response Effects 0.000 description 28
• 102000018146 globin Human genes 0.000 description 27
• 235000001014 amino acid Nutrition 0.000 description 26
• 238000001542 size-exclusion chromatography Methods 0.000 description 25
• 230000014509 gene expression Effects 0.000 description 24
• 241000282560 Macaca mulatta Species 0.000 description 23
• 239000000872 buffer Substances 0.000 description 22
• 230000004872 arterial blood pressure Effects 0.000 description 21
• 239000000539 dimer Substances 0.000 description 20
• 238000006116 polymerization reaction Methods 0.000 description 20
• 239000013615 primer Substances 0.000 description 20
• 238000010367 cloning Methods 0.000 description 19
• 239000000523 sample Substances 0.000 description 19
• 239000003814 drug Substances 0.000 description 18
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 18
• 239000000178 monomer Substances 0.000 description 18
• 239000012528 membrane Substances 0.000 description 16
• 229920000642 polymer Polymers 0.000 description 16
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 15
• 108010064719 Oxyhemoglobins Proteins 0.000 description 15
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
• 238000002474 experimental method Methods 0.000 description 15
• 238000002347 injection Methods 0.000 description 15
• 239000007924 injection Substances 0.000 description 15
• 238000004519 manufacturing process Methods 0.000 description 15
• 235000012054 meals Nutrition 0.000 description 15
• 210000000056 organ Anatomy 0.000 description 15
• 239000002244 precipitate Substances 0.000 description 15
• 241000894007 species Species 0.000 description 15
• 238000006467 substitution reaction Methods 0.000 description 15
• 108020004414 DNA Proteins 0.000 description 14
• 238000011156 evaluation Methods 0.000 description 14
• 239000002773 nucleotide Substances 0.000 description 14
• 125000003729 nucleotide group Chemical group 0.000 description 14
• 238000002360 preparation method Methods 0.000 description 14
• 238000012163 sequencing technique Methods 0.000 description 14
• 208000007056 sickle cell anemia Diseases 0.000 description 14
• 108090000765 processed proteins & peptides Proteins 0.000 description 13
• 230000005855 radiation Effects 0.000 description 13
• 210000002966 serum Anatomy 0.000 description 13
• 108020004705 Codon Proteins 0.000 description 12
• 108091034117 Oligonucleotide Proteins 0.000 description 12
• 125000003275 alpha amino acid group Chemical group 0.000 description 12
• 230000008859 change Effects 0.000 description 12
• 230000001332 colony forming effect Effects 0.000 description 12
• 230000007423 decrease Effects 0.000 description 12
• 230000030136 gastric emptying Effects 0.000 description 12
• 229920006008 lipopolysaccharide Polymers 0.000 description 12
• 229920001184 polypeptide Polymers 0.000 description 12
• 102000004196 processed proteins & peptides Human genes 0.000 description 12
• 239000011541 reaction mixture Substances 0.000 description 12
• 239000007983 Tris buffer Substances 0.000 description 11
• 230000001154 acute effect Effects 0.000 description 11
• 238000004458 analytical method Methods 0.000 description 11
• 239000003633 blood substitute Substances 0.000 description 11
• 230000000747 cardiac effect Effects 0.000 description 11
• 239000003446 ligand Substances 0.000 description 11
• 238000002156 mixing Methods 0.000 description 11
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 11
• 206010002091 Anaesthesia Diseases 0.000 description 10
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
• 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 10
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 10
• 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 10
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
• 238000011887 Necropsy Methods 0.000 description 10
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
• 230000037005 anaesthesia Effects 0.000 description 10
• 238000004132 cross linking Methods 0.000 description 10
• 235000018417 cysteine Nutrition 0.000 description 10
• 108010002255 deoxyhemoglobin Proteins 0.000 description 10
• 239000000499 gel Substances 0.000 description 10
• 231100000219 mutagenic Toxicity 0.000 description 10
• 230000003505 mutagenic effect Effects 0.000 description 10
• 230000008569 process Effects 0.000 description 10
• 239000004971 Cross linker Substances 0.000 description 9
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
• 108091005886 Hemoglobin subunit gamma Proteins 0.000 description 9
• 102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 description 9
• 210000000601 blood cell Anatomy 0.000 description 9
• 238000002512 chemotherapy Methods 0.000 description 9
• 108010074807 diaspirin-cross-linked hemoglobin Proteins 0.000 description 9
• 238000005534 hematocrit Methods 0.000 description 9
• 210000000130 stem cell Anatomy 0.000 description 9
• 238000000108 ultra-filtration Methods 0.000 description 9
• 102100030826 Hemoglobin subunit epsilon Human genes 0.000 description 8
• 108091005879 Hemoglobin subunit epsilon Proteins 0.000 description 8
• 108091005905 Hemoglobin subunit zeta Proteins 0.000 description 8
• 239000008156 Ringer's lactate solution Substances 0.000 description 8
• 230000008901 benefit Effects 0.000 description 8
• 230000004071 biological effect Effects 0.000 description 8
• 210000001772 blood platelet Anatomy 0.000 description 8
• ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 8
• 238000010276 construction Methods 0.000 description 8
• 239000008151 electrolyte solution Substances 0.000 description 8
• 230000002068 genetic effect Effects 0.000 description 8
• 229940050410 gluconate Drugs 0.000 description 8
• 230000000004 hemodynamic effect Effects 0.000 description 8
• 208000014674 injury Diseases 0.000 description 8
• 230000010354 integration Effects 0.000 description 8
• 229910052742 iron Inorganic materials 0.000 description 8
• 210000002540 macrophage Anatomy 0.000 description 8
• 238000005259 measurement Methods 0.000 description 8
• 238000000746 purification Methods 0.000 description 8
• 238000001959 radiotherapy Methods 0.000 description 8
• 102220072205 rs794728064 Human genes 0.000 description 8
• 238000012453 sprague-dawley rat model Methods 0.000 description 8
• 210000002784 stomach Anatomy 0.000 description 8
• 239000013638 trimer Substances 0.000 description 8
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
• 108091026890 Coding region Proteins 0.000 description 7
• 102100030387 Hemoglobin subunit zeta Human genes 0.000 description 7
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
• 101150087698 alpha gene Proteins 0.000 description 7
• 238000003556 assay Methods 0.000 description 7
• 230000036772 blood pressure Effects 0.000 description 7
• 230000003788 cerebral perfusion Effects 0.000 description 7
• 239000003795 chemical substances by application Substances 0.000 description 7
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 7
• 238000011161 development Methods 0.000 description 7
• 230000018109 developmental process Effects 0.000 description 7
• 230000029087 digestion Effects 0.000 description 7
• 238000010494 dissociation reaction Methods 0.000 description 7
• 230000005593 dissociations Effects 0.000 description 7
• 230000006870 function Effects 0.000 description 7
• 230000004927 fusion Effects 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 208000010125 myocardial infarction Diseases 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• 229940124597 therapeutic agent Drugs 0.000 description 7
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• 241000588724 Escherichia coli Species 0.000 description 6
• 206010021143 Hypoxia Diseases 0.000 description 6
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 6
• KFKWRHQBZQICHA-STQMWFEESA-N Leu-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 6
• 239000004367 Lipase Substances 0.000 description 6
• 102000004882 Lipase Human genes 0.000 description 6
• 108090001060 Lipase Proteins 0.000 description 6
• 108091028043 Nucleic acid sequence Proteins 0.000 description 6
• 238000000137 annealing Methods 0.000 description 6
• 210000004556 brain Anatomy 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 238000004587 chromatography analysis Methods 0.000 description 6
• 239000003431 cross linking reagent Substances 0.000 description 6
• 229910001873 dinitrogen Inorganic materials 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 238000009472 formulation Methods 0.000 description 6
• 108010036302 hemoglobin AS Proteins 0.000 description 6
• 229960003299 ketamine Drugs 0.000 description 6
• 235000019421 lipase Nutrition 0.000 description 6
• 238000011068 loading method Methods 0.000 description 6
• 230000014759 maintenance of location Effects 0.000 description 6
• WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 6
• 230000036581 peripheral resistance Effects 0.000 description 6
• 239000008363 phosphate buffer Substances 0.000 description 6
• 238000010791 quenching Methods 0.000 description 6
• 230000000171 quenching effect Effects 0.000 description 6
• 238000013222 sprague-dawley male rat Methods 0.000 description 6
• 239000011550 stock solution Substances 0.000 description 6
• 238000001356 surgical procedure Methods 0.000 description 6
• 230000000451 tissue damage Effects 0.000 description 6
• 231100000827 tissue damage Toxicity 0.000 description 6
• 239000013598 vector Substances 0.000 description 6
• 210000003462 vein Anatomy 0.000 description 6
• AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 5
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
• 102000003951 Erythropoietin Human genes 0.000 description 5
• 108090000394 Erythropoietin Proteins 0.000 description 5
• 206010015866 Extravasation Diseases 0.000 description 5
• 241000699670 Mus sp. Species 0.000 description 5
• HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 5
• 230000002776 aggregation Effects 0.000 description 5
• 238000004220 aggregation Methods 0.000 description 5
• 230000009286 beneficial effect Effects 0.000 description 5
• 210000001185 bone marrow Anatomy 0.000 description 5
• 230000002759 chromosomal effect Effects 0.000 description 5
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 5
• 230000006735 deficit Effects 0.000 description 5
• 238000001514 detection method Methods 0.000 description 5
• 229940105423 erythropoietin Drugs 0.000 description 5
• 230000007717 exclusion Effects 0.000 description 5
• 230000036251 extravasation Effects 0.000 description 5
• 239000012537 formulation buffer Substances 0.000 description 5
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
• 230000002209 hydrophobic effect Effects 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 210000004698 lymphocyte Anatomy 0.000 description 5
• 238000012544 monitoring process Methods 0.000 description 5
• 210000003205 muscle Anatomy 0.000 description 5
• 231100000350 mutagenesis Toxicity 0.000 description 5
• 238000002703 mutagenesis Methods 0.000 description 5
• 230000003647 oxidation Effects 0.000 description 5
• 238000007254 oxidation reaction Methods 0.000 description 5
• 238000006213 oxygenation reaction Methods 0.000 description 5
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 5
• 239000000843 powder Substances 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 108091008146 restriction endonucleases Proteins 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 239000000176 sodium gluconate Substances 0.000 description 5
• 235000012207 sodium gluconate Nutrition 0.000 description 5
• 229940005574 sodium gluconate Drugs 0.000 description 5
• 230000009885 systemic effect Effects 0.000 description 5
• 230000002792 vascular Effects 0.000 description 5
• XQUPVDVFXZDTLT-UHFFFAOYSA-N 1-[4-[[4-(2,5-dioxopyrrol-1-yl)phenyl]methyl]phenyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C(C=C1)=CC=C1CC1=CC=C(N2C(C=CC2=O)=O)C=C1 XQUPVDVFXZDTLT-UHFFFAOYSA-N 0.000 description 4
• 241000282693 Cercopithecidae Species 0.000 description 4
• 101100284769 Drosophila melanogaster hemo gene Proteins 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
• 206010020772 Hypertension Diseases 0.000 description 4
• 206010061216 Infarction Diseases 0.000 description 4
• 208000032382 Ischaemic stroke Diseases 0.000 description 4
• PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 4
• GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 4
• 229910019142 PO4 Inorganic materials 0.000 description 4
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
• 238000012300 Sequence Analysis Methods 0.000 description 4
• 241000282887 Suidae Species 0.000 description 4
• 206010047139 Vasoconstriction Diseases 0.000 description 4
• 230000003187 abdominal effect Effects 0.000 description 4
• 229960004308 acetylcysteine Drugs 0.000 description 4
• 239000011543 agarose gel Substances 0.000 description 4
• 230000003281 allosteric effect Effects 0.000 description 4
• 238000005349 anion exchange Methods 0.000 description 4
• 230000033228 biological regulation Effects 0.000 description 4
• 230000005587 bubbling Effects 0.000 description 4
• 230000002490 cerebral effect Effects 0.000 description 4
• 238000010382 chemical cross-linking Methods 0.000 description 4
• 238000007385 chemical modification Methods 0.000 description 4
• 230000015271 coagulation Effects 0.000 description 4
• 238000005345 coagulation Methods 0.000 description 4
• 238000005034 decoration Methods 0.000 description 4
• 238000011026 diafiltration Methods 0.000 description 4
• 239000012470 diluted sample Substances 0.000 description 4
• 230000003467 diminishing effect Effects 0.000 description 4
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 238000001962 electrophoresis Methods 0.000 description 4
• 229940088598 enzyme Drugs 0.000 description 4
• 239000006277 exogenous ligand Substances 0.000 description 4
• 238000000605 extraction Methods 0.000 description 4
• 210000005003 heart tissue Anatomy 0.000 description 4
• 238000010438 heat treatment Methods 0.000 description 4
• BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 4
• 229940025294 hemin Drugs 0.000 description 4
• 238000004128 high performance liquid chromatography Methods 0.000 description 4
• 238000004191 hydrophobic interaction chromatography Methods 0.000 description 4
• 230000007574 infarction Effects 0.000 description 4
• 230000003993 interaction Effects 0.000 description 4
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
• 210000005240 left ventricle Anatomy 0.000 description 4
• 210000000265 leukocyte Anatomy 0.000 description 4
• 239000012299 nitrogen atmosphere Substances 0.000 description 4
• 235000015097 nutrients Nutrition 0.000 description 4
• 230000036961 partial effect Effects 0.000 description 4
• 230000007170 pathology Effects 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
• 239000010452 phosphate Substances 0.000 description 4
• 229920003192 poly(bis maleimide) Polymers 0.000 description 4
• 230000000379 polymerizing effect Effects 0.000 description 4
• 238000005086 pumping Methods 0.000 description 4
• 238000011084 recovery Methods 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 150000003839 salts Chemical class 0.000 description 4
• 238000002741 site-directed mutagenesis Methods 0.000 description 4
• 239000001488 sodium phosphate Substances 0.000 description 4
• 229910000162 sodium phosphate Inorganic materials 0.000 description 4
• 235000011008 sodium phosphates Nutrition 0.000 description 4
• 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
• 206010043554 thrombocytopenia Diseases 0.000 description 4
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
• 230000025033 vasoconstriction Effects 0.000 description 4
• 238000005303 weighing Methods 0.000 description 4
• 229920000936 Agarose Polymers 0.000 description 3
• 239000004382 Amylase Substances 0.000 description 3
• 102000013142 Amylases Human genes 0.000 description 3
• 108010065511 Amylases Proteins 0.000 description 3
• 238000011731 BALB/cByJ (JAX™ mouse strain) Methods 0.000 description 3
• 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 3
• CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 3
• 201000008808 Fibrosarcoma Diseases 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 239000004471 Glycine Substances 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101001009007 Homo sapiens Hemoglobin subunit alpha Proteins 0.000 description 3
• 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 3
• 101001035503 Homo sapiens Hemoglobin subunit delta Proteins 0.000 description 3
• 101001083591 Homo sapiens Hemoglobin subunit epsilon Proteins 0.000 description 3
• 101000843058 Homo sapiens Hemoglobin subunit zeta Proteins 0.000 description 3
• 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
• 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
• 208000002193 Pain Diseases 0.000 description 3
• 239000004695 Polyether sulfone Substances 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 206010040070 Septic Shock Diseases 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 239000000654 additive Substances 0.000 description 3
• 230000002411 adverse Effects 0.000 description 3
• 108010053584 alpha-Globins Proteins 0.000 description 3
• 230000004075 alteration Effects 0.000 description 3
• 125000000539 amino acid group Chemical group 0.000 description 3
• 235000019418 amylase Nutrition 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 230000000692 anti-sense effect Effects 0.000 description 3
• 239000003963 antioxidant agent Substances 0.000 description 3
• 235000006708 antioxidants Nutrition 0.000 description 3
• 230000001174 ascending effect Effects 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• 210000003651 basophil Anatomy 0.000 description 3
• 230000017531 blood circulation Effects 0.000 description 3
• 238000009530 blood pressure measurement Methods 0.000 description 3
• 230000036760 body temperature Effects 0.000 description 3
• 229910021538 borax Inorganic materials 0.000 description 3
• 208000029028 brain injury Diseases 0.000 description 3
• 231100001012 cardiac lesion Toxicity 0.000 description 3
• 210000004413 cardiac myocyte Anatomy 0.000 description 3
• 230000002612 cardiopulmonary effect Effects 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 150000001875 compounds Chemical class 0.000 description 3
• 238000012790 confirmation Methods 0.000 description 3
• 239000013078 crystal Substances 0.000 description 3
• 230000002939 deleterious effect Effects 0.000 description 3
• 238000010790 dilution Methods 0.000 description 3
• 239000012895 dilution Substances 0.000 description 3
• AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical class C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 3
• 210000003979 eosinophil Anatomy 0.000 description 3
• 230000000925 erythroid effect Effects 0.000 description 3
• 230000010437 erythropoiesis Effects 0.000 description 3
• 239000006260 foam Substances 0.000 description 3
• 235000013305 food Nutrition 0.000 description 3
• 210000003714 granulocyte Anatomy 0.000 description 3
• 101150042363 hemH gene Proteins 0.000 description 3
• 230000002008 hemorrhagic effect Effects 0.000 description 3
• 229910052739 hydrogen Inorganic materials 0.000 description 3
• 230000007954 hypoxia Effects 0.000 description 3
• 230000001146 hypoxic effect Effects 0.000 description 3
• 108010044056 leucyl-phenylalanine Proteins 0.000 description 3
• 238000012417 linear regression Methods 0.000 description 3
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• 238000007726 management method Methods 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 230000002503 metabolic effect Effects 0.000 description 3
• 210000001087 myotubule Anatomy 0.000 description 3
• 210000000440 neutrophil Anatomy 0.000 description 3
• 201000008968 osteosarcoma Diseases 0.000 description 3
• 230000001590 oxidative effect Effects 0.000 description 3
• 230000036284 oxygen consumption Effects 0.000 description 3
• 230000036407 pain Effects 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 239000008188 pellet Substances 0.000 description 3
• 230000002572 peristaltic effect Effects 0.000 description 3
• 229920006393 polyether sulfone Polymers 0.000 description 3
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
• 229920000053 polysorbate 80 Polymers 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 102200069315 rs751222088 Human genes 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• 230000036303 septic shock Effects 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 235000010339 sodium tetraborate Nutrition 0.000 description 3
• 238000002798 spectrophotometry method Methods 0.000 description 3
• 238000001228 spectrum Methods 0.000 description 3
• 229910001220 stainless steel Inorganic materials 0.000 description 3
• 239000010935 stainless steel Substances 0.000 description 3
• 239000007858 starting material Substances 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 230000004083 survival effect Effects 0.000 description 3
• 125000003396 thiol group Chemical group [H]S* 0.000 description 3
• 230000008733 trauma Effects 0.000 description 3
• 239000004474 valine Substances 0.000 description 3
• 239000005526 vasoconstrictor agent Substances 0.000 description 3
• DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 description 2
• 206010000084 Abdominal pain lower Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 206010005746 Blood pressure fluctuation Diseases 0.000 description 2
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
• 201000006474 Brain Ischemia Diseases 0.000 description 2
• UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
• 208000031229 Cardiomyopathies Diseases 0.000 description 2
• 206010008120 Cerebral ischaemia Diseases 0.000 description 2
• 208000034656 Contusions Diseases 0.000 description 2
• 241000557626 Corvus corax Species 0.000 description 2
• 102000012410 DNA Ligases Human genes 0.000 description 2
• 108010061982 DNA Ligases Proteins 0.000 description 2
• 239000003155 DNA primer Substances 0.000 description 2
• 206010012735 Diarrhoea Diseases 0.000 description 2
• 206010053155 Epigastric discomfort Diseases 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 206010015548 Euthanasia Diseases 0.000 description 2
• 206010015719 Exsanguination Diseases 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 108010081925 Hemoglobin Subunits Proteins 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• 239000012480 LAL reagent Substances 0.000 description 2
• BQVUABVGYYSDCJ-ZFWWWQNUSA-N Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-ZFWWWQNUSA-N 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 108010062374 Myoglobin Proteins 0.000 description 2
• 102100030856 Myoglobin Human genes 0.000 description 2
• 229910002651 NO3 Inorganic materials 0.000 description 2
• BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 2
• 206010028851 Necrosis Diseases 0.000 description 2
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
• 238000012408 PCR amplification Methods 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 108010016797 Sickle Hemoglobin Proteins 0.000 description 2
• 241000282898 Sus scrofa Species 0.000 description 2
• 239000004098 Tetracycline Substances 0.000 description 2
• 102000009843 Thyroglobulin Human genes 0.000 description 2
• 108010034949 Thyroglobulin Proteins 0.000 description 2
• XCTHZFGSVQBHBW-IUCAKERBSA-N Val-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])C(C)C XCTHZFGSVQBHBW-IUCAKERBSA-N 0.000 description 2
• CMIHWILCIPLTFO-UHFFFAOYSA-N [1-[2-(diphenylphosphanylmethyl)naphthalen-1-yl]naphthalen-2-yl]methyl-diphenylphosphane Chemical compound C=1C=C2C=CC=CC2=C(C=2C3=CC=CC=C3C=CC=2CP(C=2C=CC=CC=2)C=2C=CC=CC=2)C=1CP(C=1C=CC=CC=1)C1=CC=CC=C1 CMIHWILCIPLTFO-UHFFFAOYSA-N 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 206010051895 acute chest syndrome Diseases 0.000 description 2
• 238000000246 agarose gel electrophoresis Methods 0.000 description 2
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
• 235000011130 ammonium sulphate Nutrition 0.000 description 2
• 230000003321 amplification Effects 0.000 description 2
• 230000000202 analgesic effect Effects 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 210000000709 aorta Anatomy 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 210000002798 bone marrow cell Anatomy 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 229910002091 carbon monoxide Inorganic materials 0.000 description 2
• 210000000748 cardiovascular system Anatomy 0.000 description 2
• 239000005018 casein Substances 0.000 description 2
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
• 235000021240 caseins Nutrition 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 210000002421 cell wall Anatomy 0.000 description 2
• 239000000919 ceramic Substances 0.000 description 2
• 206010008118 cerebral infarction Diseases 0.000 description 2
• 239000003638 chemical reducing agent Substances 0.000 description 2
• 230000000973 chemotherapeutic effect Effects 0.000 description 2
• 239000000356 contaminant Substances 0.000 description 2
• 230000009519 contusion Effects 0.000 description 2
• 230000001186 cumulative effect Effects 0.000 description 2
• 229940127089 cytotoxic agent Drugs 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 238000006471 dimerization reaction Methods 0.000 description 2
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
• 201000010099 disease Diseases 0.000 description 2
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
• 201000006549 dyspepsia Diseases 0.000 description 2
• 235000013399 edible fruits Nutrition 0.000 description 2
• 238000010828 elution Methods 0.000 description 2
• 230000013020 embryo development Effects 0.000 description 2
• 210000003038 endothelium Anatomy 0.000 description 2
• 230000007613 environmental effect Effects 0.000 description 2
• 208000023062 epigastric abdominal pain Diseases 0.000 description 2
• 210000000267 erythroid cell Anatomy 0.000 description 2
• 238000002146 exchange transfusion Methods 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 230000002550 fecal effect Effects 0.000 description 2
• 239000000835 fiber Substances 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 206010016766 flatulence Diseases 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 108010038853 gamma-Globins Proteins 0.000 description 2
• 108010074605 gamma-Globulins Proteins 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 238000001502 gel electrophoresis Methods 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 230000003862 health status Effects 0.000 description 2
• 239000008241 heterogeneous mixture Substances 0.000 description 2
• 210000003630 histaminocyte Anatomy 0.000 description 2
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
• 239000001257 hydrogen Substances 0.000 description 2
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
• 238000001597 immobilized metal affinity chromatography Methods 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 230000002427 irreversible effect Effects 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 201000002364 leukopenia Diseases 0.000 description 2
• 231100001022 leukopenia Toxicity 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 239000006166 lysate Substances 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 238000002483 medication Methods 0.000 description 2
• 229920000609 methyl cellulose Polymers 0.000 description 2
• 239000001923 methylcellulose Substances 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 210000001616 monocyte Anatomy 0.000 description 2
• 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
• 235000019799 monosodium phosphate Nutrition 0.000 description 2
• 210000000663 muscle cell Anatomy 0.000 description 2
• 230000003387 muscular Effects 0.000 description 2
• 230000002107 myocardial effect Effects 0.000 description 2
• 208000002089 myocardial stunning Diseases 0.000 description 2
• 230000017074 necrotic cell death Effects 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 208000004235 neutropenia Diseases 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 238000003199 nucleic acid amplification method Methods 0.000 description 2
• 238000002559 palpation Methods 0.000 description 2
• 244000045947 parasite Species 0.000 description 2
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 239000012466 permeate Substances 0.000 description 2
• SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
• 229960001802 phenylephrine Drugs 0.000 description 2
• 239000002953 phosphate buffered saline Substances 0.000 description 2
• 239000003058 plasma substitute Substances 0.000 description 2
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
• 229940068968 polysorbate 80 Drugs 0.000 description 2
• 239000012451 post-reaction mixture Substances 0.000 description 2
• 239000001103 potassium chloride Substances 0.000 description 2
• 235000011164 potassium chloride Nutrition 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 238000011809 primate model Methods 0.000 description 2
• 239000012460 protein solution Substances 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• 239000004627 regenerated cellulose Substances 0.000 description 2
• 230000013878 renal filtration Effects 0.000 description 2
• 230000000241 respiratory effect Effects 0.000 description 2
• 210000002345 respiratory system Anatomy 0.000 description 2
• 230000000284 resting effect Effects 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 210000002460 smooth muscle Anatomy 0.000 description 2
• 239000012279 sodium borohydride Substances 0.000 description 2
• 229910000033 sodium borohydride Inorganic materials 0.000 description 2
• AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
• UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 2
• 229960000268 spectinomycin Drugs 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 229960002180 tetracycline Drugs 0.000 description 2
• 229930101283 tetracycline Natural products 0.000 description 2
• 235000019364 tetracycline Nutrition 0.000 description 2
• 150000003522 tetracyclines Chemical class 0.000 description 2
• 210000000115 thoracic cavity Anatomy 0.000 description 2
• 229960002175 thyroglobulin Drugs 0.000 description 2
• 230000000287 tissue oxygenation Effects 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
• 230000007306 turnover Effects 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 108010036320 valylleucine Proteins 0.000 description 2
• 210000005166 vasculature Anatomy 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
• 229960001600 xylazine Drugs 0.000 description 2
• IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
• OYRSKXCXEFLTEY-UHFFFAOYSA-N 1-[2-[2-[2-[2-(2,5-dioxopyrrol-1-yl)ethoxy]ethoxy]ethoxy]ethyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1CCOCCOCCOCCN1C(=O)C=CC1=O OYRSKXCXEFLTEY-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• OMNVYXHOSHNURL-WPRPVWTQSA-N Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMNVYXHOSHNURL-WPRPVWTQSA-N 0.000 description 1
• WUGMRIBZSVSJNP-UFBFGSQYSA-N Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UFBFGSQYSA-N 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 206010060935 Alloimmunisation Diseases 0.000 description 1
• 101000856264 Anadara inaequivalvis Globin-1 Proteins 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 206010002388 Angina unstable Diseases 0.000 description 1
• 208000032467 Aplastic anaemia Diseases 0.000 description 1
• 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
• 206010003497 Asphyxia Diseases 0.000 description 1
• 238000012935 Averaging Methods 0.000 description 1
• 238000011725 BALB/c mouse Methods 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 206010051779 Bone marrow toxicity Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• URCIPXAXHWQQHC-UHFFFAOYSA-N C1(C=CC(N1CCCC(C(C(O)CCCN1C(C=CC1=O)=O)(C(O)CCCN1C(C=CC1=O)=O)C(O)CCCN1C(C=CC1=O)=O)O)=O)=O Chemical compound C1(C=CC(N1CCCC(C(C(O)CCCN1C(C=CC1=O)=O)(C(O)CCCN1C(C=CC1=O)=O)C(O)CCCN1C(C=CC1=O)=O)O)=O)=O URCIPXAXHWQQHC-UHFFFAOYSA-N 0.000 description 1
• 206010008190 Cerebrovascular accident Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 102100031673 Corneodesmosin Human genes 0.000 description 1
• 101710139375 Corneodesmosin Proteins 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 102000018832 Cytochromes Human genes 0.000 description 1
• 108010052832 Cytochromes Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
• MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
• 108010044495 Fetal Hemoglobin Proteins 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 208000001034 Frostbite Diseases 0.000 description 1
• 230000005526 G1 to G0 transition Effects 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 206010064571 Gene mutation Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 108010078321 Guanylate Cyclase Proteins 0.000 description 1
• 102000014469 Guanylate cyclase Human genes 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 108010027616 Hemoglobin A2 Proteins 0.000 description 1
• 102000043280 Hemoglobin, zeta Human genes 0.000 description 1
• 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
• 241000499621 Hesus Species 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• CTCFZNBRZBNKAX-YUMQZZPRSA-N His-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 CTCFZNBRZBNKAX-YUMQZZPRSA-N 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• HSQGMTRYSIHDAC-BQBZGAKWSA-N Leu-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(O)=O HSQGMTRYSIHDAC-BQBZGAKWSA-N 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 206010027439 Metal poisoning Diseases 0.000 description 1
• 102000016943 Muramidase Human genes 0.000 description 1
• 108010014251 Muramidase Proteins 0.000 description 1
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
• WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
• BIMAXYPDOFZXOY-UHFFFAOYSA-N NS(O)(=O)=O.FC1=CC(F)=C(F)C(F)=C1F Chemical class NS(O)(=O)=O.FC1=CC(F)=C(F)C(F)=C1F BIMAXYPDOFZXOY-UHFFFAOYSA-N 0.000 description 1
• 101100426732 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-9 gene Proteins 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000031481 Pathologic Constriction Diseases 0.000 description 1
• QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
• 229920005372 Plexiglas® Polymers 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
• 241000700157 Rattus norvegicus Species 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 241000220317 Rosa Species 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 229920005654 Sephadex Polymers 0.000 description 1
• 239000012507 Sephadex™ Substances 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 1
• 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 1
• 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
• 208000036064 Surgical Blood Loss Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
• 208000032109 Transient ischaemic attack Diseases 0.000 description 1
• 241001325280 Tricardia watsonii Species 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 208000007814 Unstable Angina Diseases 0.000 description 1
• 238000005411 Van der Waals force Methods 0.000 description 1
• GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical compound [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 1
• XOTMZTIJOSMYFJ-MGLUWQALSA-K [Na+].[Na+].[Na+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O Chemical compound [Na+].[Na+].[Na+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XOTMZTIJOSMYFJ-MGLUWQALSA-K 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 108010011559 alanylphenylalanine Proteins 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 150000001412 amines Chemical group 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000002744 anti-aggregatory effect Effects 0.000 description 1
• 210000002376 aorta thoracic Anatomy 0.000 description 1
• 208000021328 arterial occlusion Diseases 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
• 235000015278 beef Nutrition 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000002051 biphasic effect Effects 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 238000010241 blood sampling Methods 0.000 description 1
• 231100000366 bone marrow toxicity Toxicity 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 239000008366 buffered solution Substances 0.000 description 1
• BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 229940041514 candida albicans extract Drugs 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 210000002318 cardia Anatomy 0.000 description 1
• 230000001269 cardiogenic effect Effects 0.000 description 1
• 238000012219 cassette mutagenesis Methods 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000007541 cellular toxicity Effects 0.000 description 1
• 230000003727 cerebral blood flow Effects 0.000 description 1
• 208000026106 cerebrovascular disease Diseases 0.000 description 1
• 239000013043 chemical agent Substances 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 231100000196 chemotoxic Toxicity 0.000 description 1
• 230000002604 chemotoxic effect Effects 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 150000003841 chloride salts Chemical class 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
• 210000003040 circulating cell Anatomy 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 238000011278 co-treatment Methods 0.000 description 1
• 230000001112 coagulating effect Effects 0.000 description 1
• 239000000084 colloidal system Substances 0.000 description 1
• 230000002016 colloidosmotic effect Effects 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 229940099112 cornstarch Drugs 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 238000011461 current therapy Methods 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 238000013480 data collection Methods 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 238000002283 elective surgery Methods 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 239000012149 elution buffer Substances 0.000 description 1
• 238000002297 emergency surgery Methods 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 230000002327 eosinophilic effect Effects 0.000 description 1
• 238000002270 exclusion chromatography Methods 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 210000001105 femoral artery Anatomy 0.000 description 1
• 210000003191 femoral vein Anatomy 0.000 description 1
• 230000008175 fetal development Effects 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000013020 final formulation Substances 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 238000011010 flushing procedure Methods 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000001879 gelation Methods 0.000 description 1
• 238000012239 gene modification Methods 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 108010051057 glycosylated-nitric oxide complex hemoglobin A Proteins 0.000 description 1
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
• 229960003132 halothane Drugs 0.000 description 1
• BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
• 208000010501 heavy metal poisoning Diseases 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 230000006266 hibernation Effects 0.000 description 1
• 238000012781 high pressure - size exclusion chromatography Methods 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 235000003642 hunger Nutrition 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 208000021822 hypotensive Diseases 0.000 description 1
• 230000001077 hypotensive effect Effects 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000009851 immunogenic response Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 230000003116 impacting effect Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000001524 infective effect Effects 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 239000003999 initiator Substances 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
• 208000037906 ischaemic injury Diseases 0.000 description 1
• 229960002725 isoflurane Drugs 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 108010071185 leucyl-alanine Proteins 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
• 239000004325 lysozyme Substances 0.000 description 1
• 229960000274 lysozyme Drugs 0.000 description 1
• 235000010335 lysozyme Nutrition 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 230000008774 maternal effect Effects 0.000 description 1
• 230000005906 menstruation Effects 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 235000006109 methionine Nutrition 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 210000003657 middle cerebral artery Anatomy 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 238000007491 morphometric analysis Methods 0.000 description 1
• 238000013425 morphometry Methods 0.000 description 1
• 210000002464 muscle smooth vascular Anatomy 0.000 description 1
• 206010028537 myelofibrosis Diseases 0.000 description 1
• 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• 210000000107 myocyte Anatomy 0.000 description 1
• 231100000417 nephrotoxicity Toxicity 0.000 description 1
• 230000000324 neuroprotective effect Effects 0.000 description 1
• 231100000189 neurotoxic Toxicity 0.000 description 1
• 230000002887 neurotoxic effect Effects 0.000 description 1
• 239000002840 nitric oxide donor Substances 0.000 description 1
• 239000000236 nitric oxide synthase inhibitor Substances 0.000 description 1
• 108010042248 nitrosyl hemoglobin Proteins 0.000 description 1
• 230000035761 normovolemia Effects 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 238000001543 one-way ANOVA Methods 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• QMHLJNFGMZBHIP-UHFFFAOYSA-N oxirane;propane-1,2-diol Chemical compound C1CO1.CC(O)CO QMHLJNFGMZBHIP-UHFFFAOYSA-N 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 238000012856 packing Methods 0.000 description 1
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 239000003182 parenteral nutrition solution Substances 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 229960002275 pentobarbital sodium Drugs 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 210000001778 pluripotent stem cell Anatomy 0.000 description 1
• -1 polyethylene Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 239000004926 polymethyl methacrylate Substances 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 150000004032 porphyrins Chemical class 0.000 description 1
• 238000010149 post-hoc-test Methods 0.000 description 1
• 230000002980 postoperative effect Effects 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 239000012264 purified product Substances 0.000 description 1
• 210000001187 pylorus Anatomy 0.000 description 1
• 230000003439 radiotherapeutic effect Effects 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 239000012070 reactive reagent Substances 0.000 description 1
• 238000010223 real-time analysis Methods 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 230000020874 response to hypoxia Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 210000001995 reticulocyte Anatomy 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• CSYSULGPHGCBQD-UHFFFAOYSA-N s-ethylisothiouronium diethylphosphate Chemical compound CCSC(N)=N.CCOP(O)(=O)OCC CSYSULGPHGCBQD-UHFFFAOYSA-N 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 210000003752 saphenous vein Anatomy 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 238000007086 side reaction Methods 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
• 238000004513 sizing Methods 0.000 description 1
• 239000004328 sodium tetraborate Substances 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 230000037351 starvation Effects 0.000 description 1
• 230000036262 stenosis Effects 0.000 description 1
• 208000037804 stenosis Diseases 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 210000003699 striated muscle Anatomy 0.000 description 1
• 208000023516 stroke disease Diseases 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 230000005062 synaptic transmission Effects 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 210000000779 thoracic wall Anatomy 0.000 description 1
• 230000035921 thrombopoiesis Effects 0.000 description 1
• RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
• 210000003014 totipotent stem cell Anatomy 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 201000010875 transient cerebral ischemia Diseases 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 229910052721 tungsten Inorganic materials 0.000 description 1
• 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229910052720 vanadium Inorganic materials 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 239000011534 wash buffer Substances 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 238000002424 x-ray crystallography Methods 0.000 description 1
• 239000012138 yeast extract Substances 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1